Letter from the American Psychiatric Association re: Measure 109

8/25/20–The American Psychiatric Association, a national medical specialty society representing more than 38,800 psychiatric physicians, as well as their patients and families, have concerns about Measure 109. If passed, Measure 109 would allow for the manufacturing, delivery, and administration of psilocybin for the treatment of mental health conditions. The organization believes it is unwise to authorize treatment that is not yet approved by the Food and Drug Administration (FDA) and oppose the proposal outlined in Measure 109. Read